Published in Semin Liver Dis on February 01, 2007
An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene (2009) 3.51
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Harnessing transposons for cancer gene discovery. Nat Rev Cancer (2010) 2.44
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology (2008) 2.04
Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol (2010) 1.91
Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2010) 1.87
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86
Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol (2009) 1.85
Liver cancer stem cells. J Clin Oncol (2008) 1.82
Current management strategy of hepatocellular carcinoma. World J Gastroenterol (2009) 1.79
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74
Viral hepatocarcinogenesis. Oncogene (2010) 1.73
Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66
β-Catenin loss in hepatocytes promotes hepatocellular cancer after diethylnitrosamine and phenobarbital administration to mice. PLoS One (2012) 1.56
Astrocyte elevated gene-1 and c-Myc cooperate to promote hepatocarcinogenesis in mice. Hepatology (2015) 1.56
Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol (2009) 1.55
Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling. PLoS One (2014) 1.52
Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal (2012) 1.50
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res (2009) 1.50
Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med (2007) 1.48
Inflammation Promotes Expression of Stemness-Related Properties in HBV-Related Hepatocellular Carcinoma. PLoS One (2016) 1.48
Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Dig Dis Sci (2013) 1.48
Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin (2010) 1.40
Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2013) 1.36
Wnt signaling in liver cancer. Curr Drug Targets (2008) 1.34
miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer (2010) 1.33
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33
Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer (2012) 1.32
Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2009) 1.27
Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol (2008) 1.26
From fatty liver to fibrosis: a tale of "second hit". World J Gastroenterol (2013) 1.26
An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med (2010) 1.23
Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology (2010) 1.23
MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget (2015) 1.22
The role of Hedgehog signaling in fibrogenic liver repair. Int J Biochem Cell Biol (2010) 1.18
Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol (2010) 1.16
Structure-based discovery of antagonists of nuclear receptor LRH-1. J Biol Chem (2013) 1.16
Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int (2014) 1.15
Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol (2012) 1.04
Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA). Am J Pathol (2011) 1.04
Mouse models of hepatocarcinogenesis: what can we learn for the prevention of human hepatocellular carcinoma? Oncotarget (2010) 1.03
SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis. Br J Cancer (2014) 1.03
Stem cells in hepatocarcinogenesis: evidence from genomic data. Semin Liver Dis (2010) 1.02
Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology (2013) 1.02
Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis (2010) 1.01
Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol (2010) 1.01
CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology (2014) 1.00
Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol (2014) 0.99
Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol (2015) 0.97
A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res (2014) 0.97
Decorin deficiency promotes hepatic carcinogenesis. Matrix Biol (2013) 0.97
Genetic deletion of AEG-1 prevents hepatocarcinogenesis. Cancer Res (2014) 0.96
Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin (2010) 0.95
Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol (2010) 0.94
β-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation. Cancer Lett (2013) 0.94
The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis. BMC Cancer (2013) 0.94
Implications of hedgehog signaling antagonists for cancer therapy. Acta Biochim Biophys Sin (Shanghai) (2008) 0.92
Current and future treatments for hepatocellular carcinoma. World J Gastroenterol (2015) 0.92
Hepatocellular carcinoma: Where are we? World J Exp Med (2016) 0.92
Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. J Hepatol (2013) 0.91
TPX2 Level Correlates with Hepatocellular Carcinoma Cell Proliferation, Apoptosis, and EMT. Dig Dis Sci (2015) 0.90
Genomics and proteomics in liver fibrosis and cirrhosis. Fibrogenesis Tissue Repair (2012) 0.90
Fine-needle aspiration biopsy of hepatocellular carcinoma and related hepatocellular nodular lesions in cirrhosis: controversies, challenges, and expectations. Patholog Res Int (2011) 0.89
Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci (2014) 0.89
Association of epidermal growth factor and epidermal growth factor receptor polymorphisms with the risk of hepatitis B virus-related hepatocellular carcinoma in the population of North China. Genet Test Mol Biomarkers (2013) 0.89
Alcohol consumption promotes diethylnitrosamine-induced hepatocarcinogenesis in male mice through activation of the Wnt/β-catenin signaling pathway. Cancer Prev Res (Phila) (2014) 0.89
Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget (2016) 0.88
The roles of transforming growth factor-β, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review). Int J Oncol (2014) 0.88
Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology (2012) 0.88
Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGFβ signaling. FEBS Open Bio (2014) 0.88
Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells. J Exp Clin Cancer Res (2012) 0.88
Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. Yonsei Med J (2013) 0.87
Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway. Oncotarget (2014) 0.87
Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res (2013) 0.87
Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol (2012) 0.87
Advances in non-surgical management of primary liver cancer. World J Gastroenterol (2014) 0.86
Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation. J Biol Chem (2013) 0.86
Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. J Gastroenterol (2014) 0.85
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol Lett (2015) 0.85
Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol Aspects Med (2013) 0.85
Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. J Cancer Res Clin Oncol (2010) 0.84
Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. BMC Cancer (2015) 0.84
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. Gut Liver (2013) 0.83
Next-generation sequencing: application in liver cancer-past, present and future? Biology (Basel) (2012) 0.83
Molecular signalling in hepatocellular carcinoma: Role of and crosstalk among WNT/ß-catenin, Sonic Hedgehog, Notch and Dickkopf-1. Can J Gastroenterol Hepatol (2015) 0.82
Effects of statins on the risk of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2014) 0.82
Why men are at higher risk for hepatocellular carcinoma? J Hepatol (2012) 0.82
Targeted therapy in hepatocellular carcinoma. Int J Hepatol (2011) 0.82
Gremlin in the pathogenesis of hepatocellular carcinoma complicating chronic hepatitis C: an immunohistochemical and PCR study of human liver biopsies. BMC Res Notes (2012) 0.82
Digital karyotyping reveals probable target genes at 7q21.3 locus in hepatocellular carcinoma. BMC Med Genomics (2011) 0.82
Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. Onco Targets Ther (2009) 0.82
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Hepatocellular carcinoma. Lancet (2012) 18.09
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 5.27
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17
Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05
Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest (2009) 3.62
Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Suppression of lung adenocarcinoma progression by Nkx2-1. Nature (2011) 3.27
MONKEY: identifying conserved transcription-factor binding sites in multiple alignments using a binding site-specific evolutionary model. Genome Biol (2004) 3.15
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Chemoembolization for hepatocellular carcinoma. Gastroenterology (2004) 2.89
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol (2011) 2.82
Conservation and evolution of cis-regulatory systems in ascomycete fungi. PLoS Biol (2004) 2.81
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
Position specific variation in the rate of evolution in transcription factor binding sites. BMC Evol Biol (2003) 2.67
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology (2004) 2.54
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology (2004) 2.54
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol (2012) 2.53
Activation of hepatic stellate cells--a key issue in liver fibrosis. Front Biosci (2002) 2.49
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology (2006) 2.38
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer (2009) 2.38
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev (2011) 2.29
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29
Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol (2008) 2.22
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology (2012) 2.11
Major achievements in hepatocellular carcinoma. Lancet (2009) 2.10
Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology (2002) 2.10
The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology (2008) 2.04
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. Gastroenterology (2004) 1.94
Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology (2012) 1.91
A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology (2009) 1.90
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86
Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol (2006) 1.86
MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology (2003) 1.85
Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol (2011) 1.84
Scraping fibrosis: expressway to the core of fibrosis. Nat Med (2011) 1.82
Functions of autophagy in normal and diseased liver. Autophagy (2013) 1.81
Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol (2006) 1.79
Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology (2013) 1.78
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med (2002) 1.76
Hepatic stellate cells and liver fibrosis. Compr Physiol (2013) 1.75
Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology (2009) 1.72
Staging systems in hepatocellular carcinoma. HPB (Oxford) (2005) 1.71
Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology (2006) 1.71
Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71
Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68